stockrowAxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) Operating cash flow
AxoGen, Inc.'s operating cash flow for fiscal 2025 was $812.0K, down 82.1% from $4.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $28.4M. Over the past ten years it has ranged from −$19.9M (fiscal 2019) to $4.5M (fiscal 2024); the current reading is higher than 91% of that period. AxoGen, Inc. ranks 39th of 149 Medical Devices companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $812.0K | (82.09%) |
| FY2024 | $4.5M | — |
| FY2023 | −$5.7M | — |
| FY2022 | −$16.1M | — |
| FY2021 | −$13.4M | — |
| FY2020 | −$9.6M | — |
| FY2019 | −$19.9M | — |
| FY2018 | −$17.9M | — |
| FY2017 | −$9.2M | — |
| FY2016 | −$11.2M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $16.5M | 129.00% |
| Jun 2026 | $7.2M | 361.41% |
| Mar 2026 | $1.6M | (48.49%) |
| Dec 2025 | $3.0M | (5.74%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ITGR Integer Holdings Corporation compare | $176.5M |
| INSP Inspire Medical Systems, Inc. compare | $135.0M |
| TMDX TransMedics Group, Inc. compare | $112.4M |
| NEOG Neogen Corporation compare | $85.3M |
| UFPT UFP Technologies, Inc. compare | $71.6M |
| IRTC iRhythm Holdings, Inc. compare | $55.6M |
| AXGN AxoGen, Inc. | $28.4M |
| ESTA Establishment Labs Holdings Inc. compare | −$32.3M |
| ALMR Alamar Biosciences, Inc. compare | −$100.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on AXGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement